drugset

drugset / Trial / NCT00704509

Efficacy of Bifeprunox in Patients With Schizophrenia

NCT00704509 ↗

Phase 3 Terminated 346 enrolled H. Lundbeck A/S

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of the study is to evaluate the efficacy of bifeprunox in the maintenance phase of schizophrenia compared to placebo.

Timeline

Start: 2008-06
Primary completion: 2009-08
Completion: 2009-11

Publications

Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM, Leucht S. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020 Aug 11;8(8):CD008016. doi: 10.1002/14651858.CD008016.pub3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bifeprunox	Small molecule	20 mg	Oral
Comparator	Quetiapine	Small molecule	600 mg	Oral

Indications